Effects of 5-Pyrimidinol Derivative SNK-41 on Cytokine Profile of Mice with Lewis Lung Carcinoma
- Authors: Tallerova A.V.1, Nikitin S.V.1, Kovalenko L.P.1, Kuznetsova O.S.1
-
Affiliations:
- V. V. Zakusov Research Institute of Pharmacology
- Issue: Vol 160, No 4 (2016)
- Pages: 483-485
- Section: Article
- URL: https://journals.rcsi.science/0007-4888/article/view/236745
- DOI: https://doi.org/10.1007/s10517-016-3202-z
- ID: 236745
Cite item
Abstract
We studied the effects of SNK-411, a new 5-pyrimidinol derivative, on serum cytokine profile of C57Bl/6 mice with Lewis lung carcinoma. The compound was injected intraperitoneally in doses of 25 and 50 mg/kg. A significant (by 3.5 times) increase in serum IL-4 content was detected in mice with tumors on day 9 of tumor development. In mice receiving SNK-411 in doses of 25 and 50 mg/kg, IL-4 content significantly decreased (by 4.0 and 3.6 times) on days 2–8 of carcinoma development; IL-2 content decreased by 1.4 and 1.2 times and IL-6 content decreased by 2.7 and 1.6 times, respectively, in comparison with control mice with tumors. Injections of SNK-411 in the same doses on days 8–15 of carcinoma development led to a significant decrease in IL-4 levels (by 2.2 and 4.5 times, respectively, in comparison with control mice with tumors) and did not affect serum levels of other cytokines.
About the authors
A. V. Tallerova
V. V. Zakusov Research Institute of Pharmacology
Email: olgapharm@inbox.ru
Russian Federation, Moscow
S. V. Nikitin
V. V. Zakusov Research Institute of Pharmacology
Email: olgapharm@inbox.ru
Russian Federation, Moscow
L. P. Kovalenko
V. V. Zakusov Research Institute of Pharmacology
Email: olgapharm@inbox.ru
Russian Federation, Moscow
O. S. Kuznetsova
V. V. Zakusov Research Institute of Pharmacology
Author for correspondence.
Email: olgapharm@inbox.ru
Russian Federation, Moscow